Literature DB >> 11371361

A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex.

X N Xu1, M A Purbhoo, N Chen, J Mongkolsapaya, J H Cox, U C Meier, S Tafuro, P R Dunbar, A K Sewell, C S Hourigan, V Appay, V Cerundolo, S R Burrows, A J McMichael, G R Screaton.   

Abstract

In this study, we have compared the effector functions and fate of a number of human CTL clones in vitro or ex vivo following contact with variant peptides presented either on the cell surface or in a soluble multimeric format. In the presence of CD8 coreceptor binding, there is a good correlation between TCR signaling, killing of the targets, and FasL-mediated CTL apoptosis. Blocking CD8 binding using alpha3 domain mutants of MHC class I results in much reduced signaling and reduced killing of the targets. Surprisingly, however, FasL expression is induced to a similar degree on these CTLs, and apoptosis of CTL is unaffected. The ability to divorce these events may allow the deletion of antigen-specific and pathological CTL populations without the deleterious effects induced by full CTL activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371361     DOI: 10.1016/s1074-7613(01)00133-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  25 in total

1.  Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.

Authors:  M Montes; N Rufer; V Appay; S Reynard; M J Pittet; D E Speiser; P Guillaume; J-C Cerottini; P Romero; S Leyvraz
Journal:  Clin Exp Immunol       Date:  2005-11       Impact factor: 4.330

2.  Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.

Authors:  Philippe Guillaume; Danijel Dojcinovic; Immanuel F Luescher
Journal:  Cancer Immun       Date:  2009-09-25

3.  Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients.

Authors:  Georg Alexander Rockinger; Philippe Guillaume; Amélie Cachot; Margaux Saillard; Daniel E Speiser; Georges Coukos; Alexandre Harari; Pedro J Romero; Julien Schmidt; Camilla Jandus
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

4.  Structural and functional characterization of a single-chain peptide-MHC molecule that modulates both naive and activated CD8+ T cells.

Authors:  Dibyendu Samanta; Gayatri Mukherjee; Udupi A Ramagopal; Rodolfo J Chaparro; Stanley G Nathenson; Teresa P DiLorenzo; Steven C Almo
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

5.  Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.

Authors:  Coen Govers; Cor Berrevoets; Elike Treffers-Westerlaken; Marieke Broertjes; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2012-06       Impact factor: 2.396

6.  Two-stage cooperative T cell receptor-peptide major histocompatibility complex-CD8 trimolecular interactions amplify antigen discrimination.

Authors:  Ning Jiang; Jun Huang; Lindsay J Edwards; Baoyu Liu; Yan Zhang; Carrie D Beal; Brian D Evavold; Cheng Zhu
Journal:  Immunity       Date:  2011-01-20       Impact factor: 31.745

Review 7.  Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands.

Authors:  M Campoli; S Ferrone
Journal:  Tissue Antigens       Date:  2008-08-12

8.  Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells.

Authors:  Hendrik Streeck; Jonathan S Jolin; Ying Qi; Bader Yassine-Diab; Randall C Johnson; Douglas S Kwon; Marylyn M Addo; Chanson Brumme; Jean-Pierre Routy; Susan Little; Heiko K Jessen; Anthony D Kelleher; Frederick M Hecht; Rafick-Pierre Sekaly; Eric S Rosenberg; Bruce D Walker; Mary Carrington; Marcus Altfeld
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

9.  CD8 engineered cytotoxic T cells reprogram melanoma tumor environment.

Authors:  Julie Leignadier; Stephanie Favre; Sanjiv A Luther; Immanuel F Luescher
Journal:  Oncoimmunology       Date:  2015-09-11       Impact factor: 8.110

10.  Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region.

Authors:  Linda Wooldridge; Anna Lissina; Jonathan Vernazza; Emma Gostick; Bruno Laugel; Sarah L Hutchinson; Fareed Mirza; P Rod Dunbar; Jonathan M Boulter; Meir Glick; Vincenzo Cerundolo; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Eur J Immunol       Date:  2007-05       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.